Health
Excel
Sleep Disorders Dataset – Sleep Health & Disorders Database
Sleep Disorders Dataset
The Sleep Disorders Dataset is a structured medical database containing a comprehensive list of conditions that affect sleep patterns, quality, and overall sleep health.
Sleep disorders such as insomnia, sleep apnea, and narcolepsy can significantly impact physical and mental health. These conditions are a growing focus in health research, wellness applications, and preventive healthcare.
This dataset provides organised information about sleep-related conditions, helping researchers, developers, and healthcare professionals analyse symptoms, severity, and treatment approaches.
Each record includes detailed clinical information such as disorder descriptions, affected systems, common symptoms, severity levels, and management strategies.
The dataset has been cleaned and structured for easy integration into spreadsheets, databases, and analytical tools.
It is ideal for sleep researchers, healthcare developers, wellness app creators, and data scientists working with sleep health data.
Dataset Contents
The dataset includes fields such as:
- Disorder Name
- Description
- Affected System
- Common Symptoms
- Severity Level
- Disorder Category
- Risk Factors
- Treatment / Management
Example Conditions Included
- Insomnia
- Sleep Apnea
- Narcolepsy
- Restless Legs Syndrome
- Circadian Rhythm Disorders
- Parasomnias (e.g., sleepwalking)
- Hypersomnia
- Sleep Bruxism
- REM Sleep Behavior Disorder
- Delayed Sleep Phase Disorder
...and many more sleep-related conditions.
Data Preview
17 columns
25 rows shown
| ID | Disease Name | Category | Prevalence | Inheritance Pattern | Affected Gene(s) | Chromosome Location | Key Symptoms | Typical Age of Onset | Diagnosis Methods | Available Treatments | Orphan Drug Designation | ICD-10 Code | OMIM Number | Affected System | Disease Severity | Life Expectancy Impact | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | Chronic Insomnia Disorder | Insomnia | ~6-10% of adults globally meet DSM-5/ICSD-3-TR criteria; ~30% report symptoms (AASM 2023) | Multifactorial (stress, hyperarousal, learned maladaptive associations, genetic predisposition) | Host: polygenic (MEIS1, BTBD9, CACNA1C, AUTS2 GWAS hits) | Multiple loci | Difficulty initiating/maintaining sleep or early-morning awakening >=3 nights/week for >=3 months with daytime impairment | Adults any age; peak 40-60 years | Clinical history per ICSD-3-TR; sleep diary 1-2 weeks; Insomnia Severity Index (ISI); actigraphy; PSG only if comorbid SDB suspected | CBT-I first-line (AASM 2021); FDA-approved: DORAs daridorexant (Quviviq, Jan 2022), suvorexant (Belsomra), lemborexant (Dayvigo); ramelteon (Rozerem); low-dose doxepin (Silenor); eszopiclone (Lunesta), zolpidem (Ambien) | No | F51.01 | N/A | Nervous/Sleep-Wake | Moderate | Variable |
| 2 | 2 | Short-Term Insomnia Disorder | Insomnia | ~30-40% of adults annually; ~75% resolve within 1 year; 25% progress to chronic (AASM) | Acquired (acute stressor: bereavement, medical illness, travel, work changes) | Host: polygenic predisposition | N/A | Insomnia symptoms <3 months duration, typically linked to identifiable stressor | Any age | Clinical history per ICSD-3-TR; sleep diary; rule out secondary causes | Stimulus control, sleep hygiene, brief CBT-I; short-term hypnotics if severe (zolpidem/Ambien, eszopiclone/Lunesta) limited to 2-4 weeks; treat underlying stressor | No | F51.02 | N/A | Nervous/Sleep-Wake | Mild | None |
| 3 | 3 | Other Insomnia Disorder | Insomnia | Rare; residual ICSD-3-TR category for insomnia not meeting chronic/short-term criteria | Variable (atypical presentations, partial symptoms) | Host: variable | N/A | Insomnia complaints not meeting full chronic or short-term criteria | Any age | Clinical history per ICSD-3-TR exclusion criteria | Individualized: CBT-I components, sleep hygiene education, treat contributing factors | No | F51.09 | N/A | Nervous/Sleep-Wake | Mild | None |
| 4 | 4 | Psychophysiological Insomnia | Insomnia | Most common chronic insomnia phenotype; ~1-2% of adults (ICSD-3-TR retains as subtype descriptor) | Acquired (conditioned arousal, performance anxiety about sleep) | Host: trait hyperarousal predisposition | N/A | Heightened arousal in bed, sleep effort, reversed sleep at novel locations, rumination about sleep | Adults 20-40 years | Clinical history; sleep diary showing variable sleep; ISI; PSG reveals prolonged latency | CBT-I with stimulus control and sleep restriction (first-line); relaxation training; paradoxical intention; DORAs | No | F51.04 | N/A | Nervous/Sleep-Wake | Moderate | None |
| 5 | 5 | Paradoxical Insomnia (Sleep State Misperception) | Insomnia | ~5% of chronic insomnia patients; more common in women | Acquired (perceptual mismatch between subjective and objective sleep) | Host: unknown | N/A | Severe subjective insomnia complaints with normal or near-normal objective sleep on PSG/actigraphy | Adults 30-50 years | PSG showing TST >6.5h with subjective complaint of little/no sleep; actigraphy cross-check | CBT-I with sleep education about perception; cognitive restructuring; avoid unnecessary hypnotics | No | F51.03 | N/A | Nervous/Sleep-Wake | Moderate | None |
| 6 | 6 | Idiopathic Insomnia | Insomnia | Rare; ~0.7% of population; lifelong insomnia without identifiable trigger | Likely genetic/neurodevelopmental (unknown exact etiology) | Host: putative hyperarousal trait genes | N/A | Persistent insomnia since childhood without remission; no clear precipitant | Childhood onset, persists lifelong | Clinical history of lifelong insomnia; PSG; rule out secondary causes | CBT-I adapted for lifelong course; long-term pharmacotherapy often needed (DORAs, low-dose sedating antidepressants) | No | F51.09 | N/A | Nervous/Sleep-Wake | Moderate | Variable |
| 7 | 7 | Behavioral Insomnia of Childhood - Sleep-Onset Association | Insomnia | ~10-30% of infants/toddlers; common pediatric presentation | Acquired (maladaptive sleep-onset associations: rocking, feeding, parental presence) | Host: N/A (behavioral) | N/A | Child requires specific condition to fall asleep; prolonged sleep-onset latency; frequent night wakings requiring intervention | Infants 6 months - 3 years | Parental sleep history per ICSD-3-TR; sleep diary; rule out medical causes | Graduated extinction, bedtime fading, positive routines, parental education; melatonin rarely used in children | No | Z73.810 | N/A | Nervous/Sleep-Wake | Mild | None |
| 8 | 8 | Behavioral Insomnia of Childhood - Limit-Setting Type | Insomnia | ~10-15% of preschool children; often coexists with sleep-onset association type | Acquired (inadequate enforcement of bedtime limits by caregivers) | Host: N/A | N/A | Bedtime resistance, stalling, refusal; delayed sleep onset when caregivers do not set limits | Toddlers and preschoolers 2-6 years | Parental sleep history per ICSD-3-TR | Consistent bedtime routines, clear limits, reward systems, bedtime pass, parental education | No | Z73.811 | N/A | Nervous/Sleep-Wake | Mild | None |
| 9 | 9 | Insomnia Due to Medical Condition | Insomnia | Very common; >50% of patients with chronic pain, CHF, CKD, COPD, cancer | Secondary to underlying medical disorder (pain, dyspnea, nocturia, reflux) | Host: depends on primary condition | N/A | Insomnia attributable to medical condition; improves with disease control | Any age; depends on primary illness | Clinical history; identify causative condition; sleep diary | Treat underlying condition; adjunct CBT-I; cautious hypnotics (consider drug interactions); DORAs safer than BZDs in elderly | No | G47.01 | N/A | Nervous/Sleep-Wake | Variable | Variable |
| 10 | 10 | Insomnia Due to Mental Disorder | Insomnia | ~80-90% of MDD patients; ~60-70% of GAD; comorbid with PTSD, bipolar | Secondary to psychiatric condition (depression, anxiety, PTSD, mania) | Host: depends on primary condition | N/A | Insomnia meeting criteria with concurrent mental disorder diagnosis | Adolescence-adulthood | Clinical psychiatric evaluation; sleep history; ISI; rule out primary insomnia | Treat primary psychiatric disorder (SSRIs, SNRIs); adjunct CBT-I; trazodone, mirtazapine, quetiapine off-label; DORAs | No | F51.05 | N/A | Nervous/Sleep-Wake | Variable | Variable |
| 11 | 11 | Fatal Familial Insomnia (FFI) | Insomnia | Ultra-rare; ~70 families worldwide; <1 per million (NIH GARD 2024) | Autosomal dominant prion disease | PRNP (D178N mutation with 129M on mutant allele) | 20p13 | Progressive untreatable insomnia, dysautonomia, motor/cognitive decline, coma; death within 7-36 months | Adults 30-60 years (mean 50) | Clinical features + PRNP genetic testing; PSG shows reduced sleep efficiency; FDG-PET thalamic hypometabolism | No disease-modifying therapy; supportive care; palliative sedation; experimental anti-prion therapy in trials | Yes | A81.83 | 600072 | Nervous/Prion | Severe | Reduced |
| 12 | 12 | Short Sleeper (Familial Natural Short Sleep) | Insomnia | ~1-3% of population; mutations very rare (<50 known pedigrees) | Autosomal dominant (familial); polygenic sporadic | DEC2/BHLHE41, ADRB1, NPSR1, GRM1 | 12p12.1, 10q25.3 | Habitually sleep <6h/night without daytime dysfunction; refreshed on short sleep | Childhood or adolescence | Clinical history of lifelong short sleep without impairment; actigraphy/PSG confirm TST; rule out insomnia | Generally no treatment needed; genetic counseling for families | No | G47.8 | 612371 | Nervous/Sleep-Wake | Mild | None |
| 13 | 13 | Excessive Time in Bed | Insomnia | Common in older adults; contributor to chronic insomnia (~20% of elderly insomniacs) | Acquired (behavioral, boredom, depression, retirement) | Host: N/A | N/A | Spending excessive time in bed (>9-10h) without corresponding sleep need, producing sleep fragmentation | Older adults (>65) | Sleep diary, actigraphy showing extended bed time with low sleep efficiency | Sleep restriction therapy component of CBT-I; limit bed to sleep and sex; structured daytime activity | No | Z72.821 | N/A | Nervous/Sleep-Wake | Mild | None |
| 14 | 14 | Insomnia Due to Drug or Substance | Insomnia | Common; caffeine, alcohol, stimulants, beta-agonists, steroids, SSRIs, illicit drugs | Iatrogenic/substance-induced | Host: CYP metabolizer variants affect individual sensitivity | Variable | Insomnia temporally related to drug/substance use or withdrawal | Any age | Medication/substance history; temporal correlation; urine toxicology if indicated | Discontinue or adjust offending agent; timing changes (morning stimulants); treat substance use disorder; short-term sleep aid during taper | No | F19.182 | N/A | Nervous/Sleep-Wake | Variable | Variable |
| 15 | 15 | Delayed Sleep-Wake Phase Disorder (DSWPD) | Circadian Rhythm | ~0.17% general adults; up to 7-16% of adolescents (AASM 2015 CPG) | Genetic predisposition + environmental (light exposure, schooling/work) | PER3, CRY1 variants | 1p36.23, 12q24.31 | Chronic inability to fall asleep until late (2-6 AM) and wake at desired time; normal sleep architecture when free-running | Adolescence-young adulthood | Sleep diary + actigraphy >=7 days per ICSD-3-TR; dim light melatonin onset (DLMO) phase marker | Timed bright light morning, evening melatonin 0.5-3 mg 4-6h before desired sleep (AASM strong rec); gradual advance chronotherapy | No | G47.21 | N/A | Nervous/Circadian | Moderate | None |
| 16 | 16 | Advanced Sleep-Wake Phase Disorder (ASWPD) | Circadian Rhythm | ~1% older adults; rare in young adults (<0.03%) | Sporadic (age-related) or familial (autosomal dominant FASPS) | PER2, CSNK1D, PER3, CRY2 variants in familial cases | 2q37.3, 17q25.3 | Early evening sleepiness (6-8 PM) and early morning awakening (2-5 AM); stable endogenous phase | Older adults; familial forms childhood onset | Sleep diary + actigraphy; DLMO; chronotype questionnaires (MEQ) | Evening bright light exposure; morning darkness/sunglasses; avoid daytime naps; limited pharmacotherapy | No | G47.22 | N/A | Nervous/Circadian | Mild | None |
| 17 | 17 | Familial Advanced Sleep Phase Syndrome (FASPS) | Circadian Rhythm | Ultra-rare; <200 families worldwide | Autosomal dominant | PER2 (S662G), CSNK1D (T44A), PER3, CRY2 | 2q37.3, 17q25.3, 1p36.23, 11p11.2 | Lifelong extreme advance of sleep phase (~4h earlier); fall asleep 7-8 PM, wake 3-4 AM | Childhood onset, lifelong | Family history; genetic testing (PER2/CSNK1D); DLMO showing advanced phase | Evening bright light therapy; behavioral schedule adaptation; genetic counseling | No | G47.22 | 604348 | Nervous/Circadian | Mild | None |
| 18 | 18 | Irregular Sleep-Wake Rhythm Disorder (ISWRD) | Circadian Rhythm | Most common in dementia (~25-40% AD patients, >60% institutionalized); rare in healthy adults | Acquired (neurodegeneration, reduced zeitgebers, blindness, intellectual disability) | Host: circadian pacemaker degeneration in SCN | N/A | Sleep fragmented into 3+ episodes throughout 24h without circadian pattern | Older adults with dementia; developmental disorders | Sleep diary + actigraphy >=7 days showing no stable rhythm per ICSD-3-TR | Structured daytime activity, bright light exposure, melatonin (AASM weak rec for dementia); treat dementia; environmental zeitgebers | No | G47.23 | N/A | Nervous/Circadian | Moderate | Variable |
| 19 | 19 | Non-24-Hour Sleep-Wake Rhythm Disorder (N24) | Circadian Rhythm | ~55-70% of totally blind individuals; rare in sighted (~0.5-1%) | Loss of photic entrainment (blindness); rarely sighted with unknown etiology | Host: unknown in sighted cases | N/A | Progressive daily drift of sleep onset by ~30-60 min; cyclical alternating insomnia and hypersomnia | Any age; onset with blindness | Sleep diary + actigraphy >=14 days showing progressive phase drift; serial DLMO | Tasimelteon (Hetlioz, FDA Jan 2014 orphan for N24 in blind); melatonin; bright light in sighted | Yes | G47.24 | N/A | Nervous/Circadian | Moderate | None |
| 20 | 20 | Shift Work Sleep Disorder | Circadian Rhythm | ~10-23% of shift workers; ~20% of US workforce performs shift work | Acquired (misalignment of work schedule with endogenous circadian phase) | Host: PER3 VNTR polymorphism affects tolerance | 1p36.23 | Insomnia during intended sleep or excessive sleepiness during work shifts; >=3 months | Working adults | Sleep diary + actigraphy >=14 days covering work/off days per ICSD-3-TR | Scheduled naps, strategic bright light/darkness, caffeine; modafinil (Provigil) and armodafinil (Nuvigil) FDA-approved for SWSD; short-term hypnotics for daytime sleep | No | G47.26 | N/A | Nervous/Circadian | Moderate | Variable |
| 21 | 21 | Jet Lag Disorder | Circadian Rhythm | Affects most travelers crossing >=2 time zones; worse eastward | Acquired (rapid transmeridian travel) | Host: PER3 polymorphism modulates severity | 1p36.23 | Disturbed sleep, daytime fatigue, GI symptoms, impaired function following travel >=2 time zones | Any age; travelers | Clinical history of recent transmeridian travel per ICSD-3-TR | Pre-trip phase shifting; timed light exposure; melatonin 0.5-5 mg at destination bedtime; short-acting hypnotics for sleep; caffeine for alertness | No | G47.25 | N/A | Nervous/Circadian | Mild | None |
| 22 | 22 | Circadian Rhythm Sleep-Wake Disorder, Not Otherwise Specified | Circadian Rhythm | Residual ICSD-3-TR category; prevalence unknown | Variable (mixed or atypical circadian presentations) | Host: variable | N/A | Circadian symptoms not meeting criteria for specific CRSWD types | Any age | Sleep diary + actigraphy; DLMO if available | Individualized circadian-based therapy (light, melatonin, behavioral scheduling) | No | G47.20 | N/A | Nervous/Circadian | Variable | Variable |
| 23 | 23 | Smith-Magenis Syndrome | Circadian Rhythm | 1 in 15,000-25,000 births (NORD/NIH GARD) | Autosomal dominant (de novo deletion or RAI1 mutation) | RAI1 (Retinoic Acid Induced 1); 17p11.2 microdeletion | 17p11.2 | Inverted circadian melatonin rhythm (daytime peak); intellectual disability, behavioral problems, self-injury, dysmorphism | Infancy-childhood | FISH/chromosomal microarray for 17p11.2 deletion; RAI1 sequencing; sleep actigraphy shows inverted rhythm | Tasimelteon (Hetlioz LQ) FDA-approved Dec 2020 orphan for nighttime sleep disturbances in SMS patients >=3y; beta-blockers for daytime melatonin; behavioral support | Yes | Q93.88 | 182290 | Nervous/Genetic | Severe | Reduced |
| 24 | 24 | Angelman Syndrome | Circadian Rhythm | 1 in 12,000-20,000 births (NORD/NIH GARD) | Loss of maternal UBE3A expression (15q11-q13 deletion, UPD, imprinting defect, UBE3A mutation) | UBE3A | 15q11.2-q13 | Severe sleep fragmentation with reduced need; intellectual disability, ataxia, seizures, happy demeanor, microcephaly | Infancy (detected 6-12 months) | DNA methylation analysis (15q11-q13); UBE3A sequencing; EEG; sleep actigraphy | Melatonin (effective in ~50%); behavioral sleep interventions; AEDs for seizures (valproate, clonazepam); experimental UBE3A reactivators in trials | No | Q93.51 | 105830 | Nervous/Genetic | Severe | Reduced |
| 25 | 25 | Obstructive Sleep Apnea, Adult | Sleep-Related Breathing | ~936 million adults globally (Lancet Resp Med 2019); ~30 million US adults; AHI>=5 in ~26% of 30-69y | Multifactorial (obesity, male sex, craniofacial anatomy, neuromuscular tone, genetic) | Host: polygenic (PTGER3, LPAR1, CRP variants in GWAS) | Multiple loci | Loud snoring, witnessed apneas, choking/gasping, daytime sleepiness, morning headaches, nocturia, hypertension | Adults; peak 40-60 years | PSG (gold standard) or home sleep apnea testing; AHI>=5 with symptoms or >=15 without per AASM 2023; Epworth score | CPAP first-line; oral appliances for mild-moderate; weight loss; tirzepatide (Zepbound, FDA Dec 20 2024 for moderate-severe OSA with obesity); hypoglossal nerve stimulation (Inspire, FDA 2014); UPPP/MMA surgery | No | G47.33 | N/A | Respiratory/Sleep | Variable | Variable |
- Full dataset access
- Excel format
- Instant download